Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexeo Therapeutics

9.58
+0.81009.24%
Post-market: 9.600.0200+0.21%19:54 EDT
Volume:4.08M
Turnover:36.85M
Market Cap:517.33M
PE:-3.00
High:9.59
Open:9.13
Low:8.50
Close:8.77
52wk High:11.72
52wk Low:1.45
Shares:54.00M
Float Shares:40.09M
Volume Ratio:4.11
T/O Rate:10.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1956
EPS(LYR):-3.0934
ROE:-75.32%
ROA:-41.91%
PB:3.74
PE(LYR):-3.10

Loading ...

Lexeo Therapeutics Executives Make Major Stock Moves!

TIPRANKS
·
Yesterday

Lexeo Therapeutics Chief Development Officer Sandi See Tai Reports Sale of Common Shares

Reuters
·
Yesterday

Lexeo Therapeutics CEO Richard Nolan Reports Disposal of Common Shares

Reuters
·
Yesterday

Lexeo Therapeutics price target lowered to $18 from $20 at Leerink

TIPRANKS
·
Yesterday

Lexeo Therapeutics Shares up 2.5% After Co's Stock Sale, Private Placement

THOMSON REUTERS
·
Oct 17

Lexeo Therapeutics 15.625M share Spot Secondary priced at $8.00

TIPRANKS
·
Oct 17

Lexeo Therapeutics Shares Fall 5.9% Premarket After Co's Stock Sale, Private Placement

THOMSON REUTERS
·
Oct 17

Lexeo Therapeutics Inc Announces Public Offering And Private Placement For $135 Million

Reuters
·
Oct 17

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

THOMSON REUTERS
·
Oct 17

Lexeo Therapeutics Inc - Offers 15,625,000 Shares at $8.00 per Share

THOMSON REUTERS
·
Oct 17

Lexeo Therapeutics Announces Public Offering and Concurrent Private Placement of Common Stock and Pre-Funded Warrants

Reuters
·
Oct 17

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Oct 17

Lexeo Therapeutics Initiated at Buy by Guggenheim

Dow Jones
·
Oct 15

Guggenheim Initiates Coverage on Lexeo Therapeutics With Buy Rating, $30 Price Target

MT Newswires Live
·
Oct 15

Chardan Raises Price Target on Lexeo Therapeutics to $17 From $15, Keeps Buy Rating

MT Newswires Live
·
Oct 08

Buy Rating for Lexeo Therapeutics Driven by Regulatory Progress and Promising Clinical Data on LX2006

TIPRANKS
·
Oct 08

Lexeo Therapeutics Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Oct 07

Lexeo Therapeutics price target raised to $20 from $9 at Leerink

TIPRANKS
·
Oct 07

Lexeo Therapeutics Shares Rise 28% After Positive Trial Results for Co's Heart Disease Drug

THOMSON REUTERS
·
Oct 07

Lexeo Therapeutics up 31% at $8.50 after update on LX2006 accelerated approval

TIPRANKS
·
Oct 07